Estradiol treatment of ER+ breast cancer cell lines stimulates both AGR2 expression and a twofold increase in ESR1 binding to the AGR2 promoter region as detected by chromatin immunoprecipitation (ChIP) [12, 20]. Here, ESR1 is linked to breast carcinoma.